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Introdcution
Colorectal carcinoma is the third-leading cause of can-
cer deaths in the United States. Up to 60% of patients
with colon cancer will eventually develop liver me-
tastases. Progression of such hepatic metastases is the
major cause of death in these patients. It is recognized
that tumor metastasis and progression are angiogenesis-
dependent.1 An avascular tumor rarely grows larger
than 2 to 3mm3, but, once vascularized, tumor progres-
sion is rapid.2 The angiogenic process includes cell
migration, proliferation, extracellular matrix degra-
dation, and structural reorganization.3 These steps
are regulated by the balance of proangiogenic and
antiangiogenic molecules and their receptors.3 One po-
tent proangiogenic factor is vascular endothelial growth
factor (VEGF) that can be synthesized and secreted by
both tumor and host cells. VEGF is a homodimeric 34-
to 42-kDa heparin-binding glycoprotein with mitogenic
and vascular permeability-enhancing activities for en-
dothelial cells.4 Its activity is mediated by two high-
affinity tyrosine-kinase receptors, fms-like tyrosine
kinase (flt-1) and fetal liver kinase-1 (flk-1): flk-1 is a
major regulator of angiogenesis, both in vitro and in
vivo.4,5
The p53 tumor suppressor gene is the most commonly
mutated gene in human cancer. It is correlated to poor
prognosis in colon cancer.6,7 bcl-2 is a tumor proto-
oncogene that contributes to the development and pro-
gression of colon cancer.8 Both the p53 gene and the
bcl-2 gene are involved in the regulation of apoptosis
(programmed cell death)6 and VEGF expression.1,8,9 Ki-
67 nuclear antigen is evident in all active phases of the
cell cycle, and its expression is utilized as an indicator of
Abstract
Background/Purpose. This study investigated vascular endot-
helial growth factor (VEGF) and flk-1 expression in hepatic
metastases from colon carcinoma, and their associations with
tumor angiogenesis, proliferation, and apoptosis.
Methods. Immunohistochemical studies were performed for
VEGF/flk-1, Ki-67, p53, and bcl-2 expression, and microvessel
density (MVD) in surgical specimens from 35 patients who
underwent hepatectomy for colon cancer liver metastases
between 1986 and 2001.
Results. VEGF and flk-1 were expressed mainly in the cyto-
plasm of tumor cells. High VEGF expression was associated
with high flk-1 expression (P  0.043). MVDs of less than 15
and 15 or more were found in 5 (14.3%) and 30 (85.7%) of 35
hepatic metastases, respectively. A Ki-67 index (KI) of 50%
or more was detected in 33/35 (94.3%) of tumors, and 23 of
these (65.7%) showed a KI of 85% or more. A KI of less than
50% was present in 2/35 (5.7%) of tumors. The expression of
VEGF/flk-1 was related to elevated MVD (P  0.026). VEGF
was also associated with an increased KI (P  0.025). Mutant
p53 and bcl-2 expressions were detected in 26/35 (74.3%) and
17/35 (48.6%) of liver metastases, respectively. Mutant p53
was not related to VEGF/flk-1 expression, but bcl-2 was highly
associated with flk-1 (P  0.007). The incidences of high flk-1
expression and a KI of 85% or more were significantly higher
in tumors which were both p53- and bcl-2-positive (93.3% and
73.3%) than in tumors which were negative for both (42.9%
and 14.3%; P  0.021).
Conclusions. The VEGF-flk-1 system takes part in tumor
angiogenesis, proliferation, and apoptosis in colon liver me-
tastases. The bcl-2 pathway may upregulate VEGF activity via
the flk-1 receptor. These findings are preliminary, requiring a
larger sampling in order to elucidate the role of VEGF/flk-1 in
metastatic colon cancer.
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tumor proliferation.10 In order to further understand the
role of VEGF/flk-1 in tumor angiogenesis, proliferation,
and apoptosis, we hypothesized that hepatic metastases
from colon cancer may overexpress VEGF and flk-1,
and their expressions may be associated with tumor
angiogenesis, proliferation, and apoptosis markers. This
study was designed to test this hypothesis in surgical
archival specimens of colorectal hepatic metastases.
Patients, materials, and methods
The clinical and pathologic data from 35 patients with
colon carcinoma liver metastases, who underwent
partial hepatectomy between 1986 and 2001, were
reviewed. A representative formalin-fixed paraffin-
embedded block containing both cancer and adjacent
noncancerous liver was selected from each case. Normal
liver away from the tumor margins served as internal
controls. Consecutive 4-µm sections were cut from each
selected histological block, mounted on positively
charged slides, and allowed to dry in an oven at 60°C
overnight. Sections were deparaffinized in xylene,
followed by 99.99%, 95%, and 80% isopropyl alcohol
(Fisher Scientific, Pittsburgh, PA, USA) and rehydrated
in tap water. For antigen retrieval, these sections were
immersed in 1 citrate buffer (pH 6.0; Biocare Medical,
Walnut Creek, CA, USA) for VEGF and p53, 1 re-
veal buffer (pH 6.0; Biocare Medical) for flk-1, BORG
buffer (pH 9.5; Biocare Medical) for CD31, and 1 Tris
buffer (pH 9.5; Biocare Medical) for Ki-67 and bcl-2,
and boiled for 8min in a pressure cooker (Decloaking
Chamber; Biocare Medical). This procedure unmasked
the epitopes from the formalin bonds, allowing better
antibody recognition. Endogenous peroxidase activity
was quenched with 3% hydrogen peroxide (H2O2).
Immunohistochemical staining (IHC) was performed
with the streptavidin-biotin method, using a Ventana
NEXES automated immunostainer (Ventana Medical
Systems, Tucson, AZ, USA). Mouse monoclonal pri-
mary antibodies were used for VEGF (sc-7269, IgG2a;
Santa Cruz Biotechnology, Santa Cruz, CA, USA;
1:150 dilution), flk-1 (sc-6251, IgG1; Santa Cruz Bio-
technology; 1:100 dilution), human endothelial cells
(CD31; clone JC/70A, IgG1; DAKO, Carpinteria, CA,
USA; 1:20 dilution), Ki-67 (Mib-1, IgG1; Immunotech,
Beckman Coulter, Marseille, France; 1:40 dilution), p53
(clone DO-7, IgG2b; DAKO, labeling both wild-
type and mutant p53 protein, 1:100 dilution), bcl-2
(clone 124, IgG1; DAKO, 1:40 dilution), and
carcinoembryonic antigen (CEA; clone CEJ065, IgG;
Immunotech, prediluted). The secondary antibody,
biotinylated goat antimouse and rabbit IgG (Biocare
Medical) and a tertiary label with streptavidin-horse-
radish peroxidase (HRP) complex were added auto-
matically. The immunoperoxidase staining was devel-
oped using 3,3-diaminobenzidine tetrahydrochloride
(DAB). Negative controls were prepared by omitting
the primary antibody and substitution with an irrelevant
mouse antibody. Tissues known to express selected
antigens were selected as positive controls for each
antibody (breast carcinoma for VEGF and CD31, colon
cancer for flk-1, lymph nodes for Ki-67 and bcl-2, and
squamous cell carcinoma for p53). All slides were
counterstained with hematoxylin and mounted with
coverslipping film (Tissue-Tek, Sakura, Japan).
The intensity of VEGF/flk-1 and CEA staining was
assessed semiquantitatively under a light microscope,
using a score of 0 to 3: 0, negative; 1, weak or low
intensity; 2, intermediate or moderate intensity; and
3, strong or high intensity. For analyses, VEGF/flk-1
expression was classified as “low” if the score was 0 or
1; or “high” if the score was 2 or 3.11 The intensity
was judged relative to an intensely stained positive con-
trol (3). Homogeneity of staining was determined,
together with the localization of staining and its
reproducibility.
Microvessel density (MVD) is an index of angiogen-
esis and was assessed using a technique modified from
those of Weidner et al.12 and Vermeulen et al.13 The
entire section was systematically scanned at a magnifi-
cation of 100 to search for areas of intense
neovascularization at the tumor-liver interface, com-
monly called “hot spots” (Fig. 1A). These were identi-
fied as having the highest density of brown-staining,
CD31-positive cells or cell clusters. Whenever a highly
vascularized area was evident at magnification 100,
the individual microvessels were counted on a single
200 field in this area, using a light microscope-monitor
system (Color Video Printer; UP-5600MD; Sony,
Tokyo, Japan). Any brown-stained structure clearly
separated from adjacent microvessels was regarded as a
single countable microvessel. Neither vessel lumen nor
the presence of red blood cells was used to define a
microvessel, and exclusion criteria based on size were
not used. The mean microvessel count of five 200
fields per sample determined a tumor MVD.
Proliferation activity of cancer cells were evaluated
by the Ki-67 index (KI). The KI was calculated as the
percentage of tumor cells staining positive with Ki-67
antibody in ten fields at magnification 400. The ex-
pression of p53 and that of bcl-2 were considered posi-
tive if greater than 10% of cancer cells demonstrating
staining.13,14 The percentages of Ki-67, p53, and bcl-2
expression were also counted under the light micro-
scope-monitor system. Hematoxylin-and-eosin staining
was performed for histopathological assessment.
For quality control, MVD and KI were counted by an
independent investigator, and the staining results were
evaluated independently at the same calibration slides
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by two investigators. Every investigator was blinded to
every other investigator’s interpretation and the patient
outcome, and each investigator was also unaware of
each marker evaluation score. The results for flk-1, p53,
bcl-2, and CEA were concordant. The agreement for
VEGF was 97.1%, and a final result was obtained by
consensus in one case.
Clinical and pathological features collected included
age, sex, type of hepatic metastases (synchronus vs
metachronous), tumor number, largest size, lobar
distribution (unilobar vs bilobar), and differentiation
(defined as well-, moderately, or poorly differentiated).
Values are given as numbers and/or percentages. The
Fisher exact test was used for statistical analysis (Primer
of biostatistics, McGraw-Hill, 1997). Statistical signifi-
cance was considered at P  0.05.
Results
The 35 patients included 16 men and 19 women, with a
mean age of 61 years (range, 39–76 years). All patients
underwent partial hepatectomy. Thirty-one of 35
(88.6%) specimens were from metachronous hepatic
metastases, and 4 (11.4%) were from synchronous me-
tastases. Nineteen of 35 (54.3%) patients had a single
tumor and 16 (45.7%) patients had multiple (2) tu-
mors. In 27 (77.1%) patients the tumors were unilobar,
while in 8 (22.9%) patients they were bilobar. The mean
largest tumor size was 5.3cm (median, 5.0cm; range,
1.0–12.5cm). Tumor size of less than 4cm was found in
13 (37.1%) patients, and a size of 4cm or more in 22
(62.9%) patients. The tumors were moderately differ-
entiated in 27 (77.1%) cases and 8 (22.9%) were poorly
differentiated.
All cases stained strongly for CEA (2 to 3). Both
VEGF and flk-1 exhibited predominantly cytoplasmic
staining in tumor cells (Fig. 1B,C), but VEGF immu-
noreactivity also showed a heterogeneous staining
pattern, with both cytoplasmic and nuclear staining in
12 of 35 (34.3%) cases. VEGF was more frequently
expressed in cancer tissue than in adjacent liver tissue.
Some tumor samples showed a gradient of increased
intensity toward the infiltrating edge of the tumor cells.
VEGF expression was “high” (2/3) in 29 of 35
(82.9%) and “low” (0/1) in 6/35 (17.1%). Flk-1 ex-
pression was “high” in 25/35 (71.4%) and “low” in 10/35
(28.6%). The statistical test showed a significant asso-
ciation between increased VEGF and flk-1 expressions
(P  0.043; Table 1). VEGF and flk-1 were also ex-
pressed in the endothelial cells.
Tumor MVD of less than 15 was found in 5 of 35
(14.3%) hepatic metastases and an MVD of 15 or more
was observed in 30 (85.7%) tumors. KI values of 50% or
more and 85% or more were detected in 33/35 (94.3%)
and 23/35 (65.7%) tumors, respectively. Only 2/35
(5.7%) of metastases showed a KI values of less than
50%. The expression of both VEGF and flk-1 was
strongly related to MVD (P  0.026). There was also an
association between VEGF and KI (P  0.025; Table 2).
Positive nuclear staining for p53 was detected in 26 of
35 (74.3%) cases. The p53 nuclear staining was diffuse,
Fig. 1A–C. Microvessel density (MVD) was counted at the
tumor-liver interface “hot spot” (A), as an index of angiogen-
esis. Strong cytoplasmic staining (3) for vascular endothelial
growth factor (VEGF) (B) and flk-1 (C) was present in he-
patic metastatic tumor cells from colon cancer. A 200; B,C
400
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Table 1. Association between VEGF and flk-1 expression
VEGF
flk-1 Low (/1) High (2/3)
Low (/1) 4 6
High (2/3) 2 23
The Fisher exact test showed a linear trend between vascular endothe-
lial growth factor (VEGF) and flk-1 expression; P  0.043
Table 3. Relationship between p53/bcl-2 coexpression and the incidences of high VEGF/flk-1 expression, MVD  15, and KI 
85%
n (%) High VEGF High flk-1
(Total n  35) (2/3) (2/3) MVD  15 KI  85%
p53/bcl-2 15 (42.9%) 13 (86.7%) 14 (93.3%) 13 (86.7%) 11 (73.3%)
p53/bcl-2 7 (20.0%) 7 (100%) 3 (42.9%)* 7 (100%) 1 (14.3%)**
p53/bcl-2 tumors vs p53/bcl-2 tumors, * P  0.021; ** P  0.020
Table 2. Relationship between VEGF/flk-1 expression and clinical or immuno-histochemical markers
VEGF flk-1 P value
Low (/1) High (2/3) Low (/1) High (2/3) VEGF, flk-1
Differentiation
Poor 3 5 3 5 0.117, 0.661
Moderate 3 24 7 20
Tumor size
4cm 3 10 4 9 0.648, 1.000
4cm 3 19 6 16
MVD
15 3 2 4 1 0.026, 0.017
15 3 27 6 24
KI
50% 2 0 2 0 0.025, 0.076
50% 4 29 8 25
p53
Negative 0 9 4 5 0.304, 0.393
Positive 6 20 6 20
bcl-2
Negative 4 14 9 9 0.658, 0.007
Positive 2 15 1 16
MVD, microvessel density; KI, Ki-67 index
with little variation. p53-positivity and high VEGF ex-
pression coexisted in 20 of 35 (57.1%) patients. There
were no cases showing both p53 negativity and low
VEGF expression. Immunoreactivity for bcl-2 was
mainly cytoplasmic, and was principally localized to the
apical portion of the tumor cells. Seventeen (48.6%)
tumors were bcl-2 positive and 18 (51.4%) were nega-
tive. There was no relationship between p53 or bcl-2
and the KI (P  0.486). Both p53 and bcl-2 positivity
(p53/bcl-2) was observed in 15 of 35 (42.9%) tumors,
and both p53 and bcl-2 negativity (p53/bcl-2) was ob-
served in 7 (20.0%; Table 3). Expression of VEGF
showed no association with either p53 or bcl-2 (P 
0.304 and P  0.658, respectively; Table 2). flk-1 expres-
sion was significantly related to bcl-2 expression at a
direct level ratio (P  0.007), but p53 expression was
not (P  0.393). p53/bcl-2 tumors were associated
with higher incidences of high flk-1 expression (14 of 15;
93.3%) and a KI of 85% or more (11 of 15; 73.3%)
compared with p53/bcl-2 tumors (3 of 7; 42.9%; P 
0.021, and 1 of 7; 14.3%; P  0.020, respectively) (Table
3, Fig. 2). There were no differences in the incidences of
high VEGF expression and an MVD of 15 or more
between p53/bcl-2 tumors (13 of 15; 86.7% and 13 of
15; 86.7%) and p53/bcl-2 tumors (7 of 7; 100% and 7
of 7; 100%) respectively (P  1.000; Table 3, Fig. 2).
Sex, age, CEA, tumor number, largest size, lobar
distribution, differentiation, and type of hepatic me-
tastases showed no association with VEGF/flk-1, p53,
and/or bcl-2 expression (P 	 0.05).
Discussion
It is widely accepted that angiogenesis is essential for
tumor progression and the development of metastasis.1
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A higher degree of tumor vascularization increases the
likelihood that tumor cells will enter the circulatory
system and successfully metastasize. VEGF and its re-
ceptors play an important role in the induction of tumor
angiogenesis. VEGF overexpression has been reported
in a variety of solid tumors, including breast, bladder,
renal, gastric, colorectal, liver, and pancreatic carcino-
mas.7,15 Several studies have shown that VEGF expres-
sion is related to the presence of vascular invasion and
liver metastasis in colon cancer.7,14 Traditionally, VEGF
is thought to act in a paracrine manner via its receptors
flt-1 and flk-1, which are both predominantly expressed
in endothelial cells.16,17 flk-1 is a major regulatory of
VEGF-receptor interaction and induces tumor growth
and angiogenesis.18
Coexpression of VEGF and flk-1 has been identified
in human pancreatic and prostate cancer cells by immu-
nohistochemical studies.17,19 An in vitro study has
also shown that flk-1 mediates the mitogenic function
in response to VEGF, and dominant-negative flk-1
results in disruption of VEGF-mediated signal trans-
duction in pancreatic cancer cell lines.17 These observa-
tions imply the existence of a VEGF-flk-1 autocrine
loop with a direct mitogenic effect in tumor cells. In
our study, we found that both VEGF and flk-1 were
coexpressed in tumor cells, in addition to endothelial
cells, in colon hepatic metastases. High levels of VEGF
and flk-1 expression occurred in 82.9% and 71.4% of
tumors, respectively. Higher VEGF expression was as-
sociated with higher flk-1 expression (P  0.043). These
findings support the idea that the VEGF-flk-1 system
works not only via a paracrine loop but also through an
autocrine pathway in hepatic metastases from colon
cancer.
The extent of MVD correlates with tumor angiogen-
esis and hematogenous metastasis of colorectal can-
cer.7,13,14,20,21 Patients with synchronous colon carcinoma
metastasis have higher vessel counts in their primary
tumor than patients with no clinical metastasis.20,21
There is a direct correlation between the expression
of VEGF, vessel counts, and the development of me-
tastases.20,21 Studies have demonstrated that both the
microvessel count and VEGF expression are prognostic
indicators in colorectal cancer.21,22 Ki-67 proliferative
activity is inversely correlated with overall and disease-
free survivals.10 Our results showed that VEGF/flk-1
expression was related to MVD. VEGF expression was
also associated with a high KI. These findings suggest
that VEGF and/or flk-1 are involved in regulating the
angiogenesis and proliferation of hepatic metastases
from colon cancer, and VEGF-expressing tumor cells
have a proliferation advantage. Although the associa-
tion of flk-1 and KI did not reach statistical significance
in our study (P  0.076; Table 2), this may be due to the
small number of cases examined.
Mutation in p53 and aberrant expression of bcl-2
allow continued tumor proliferation and inhibition
of apoptosis.23 Coexpression of the bcl-2 and mutant
p53 proteins was detected in 38% of primary colon
cancers.6 In 62.9% of our patients, both p53 and
bcl-2 were either identified or absent. Mutant p53
upregulates VEGF and diminishes angiogenesis
inhibitor thrombospondin-1.1,9 Reintroduction of the
wild-type p53 gene into colon cancer cells results
in a dose-dependent decrease in VEGF mRNA and
protein expression.24 There is an association between
overexpression of mutant p53 protein, increased MVD,
tumor growth, and VEGF expression in colon cancer.7
Kang et al.14 reported that p53 and VEGF staining sta-
tus were identical in 65.6% of colorectal carcinomas,
and suggested that a p53-VEGF pathway regulates the
angiogenesis of colon carcinoma. Other studies have
not confirmed these relationships.12 We found that p53
was not statistically associated with VEGF and flk-1
Fig. 2A,B. The incidences of high VEGF or flk-1 expression
(A) and MVD  15 or Ki-67 index (KI)  85% (B) relative to
p53/bcl-2 (black bars) and p53/bcl-2 (white bars) tumors
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expression. Although bcl-2 expression was not related
to VEGF, bcl-2 was associated with flk-1 expression
(P  0.007; Table 2). p53 and high VEGF expression
coincided in 20 of 35 (57.1%) tumors. p53/bcl-2 tu-
mors had significantly higher incidences of high flk-1
expression (93.3%) and a KI of 85% or more (73.3%)
as compared to p53/bcl-2 tumors (42.9% and 14.3%;
P  0.021). However, there were no differences in the
incidences of high VEGF expression and an MVD of 15
or more between p53/bcl-2 and p53/bcl-2 tumors
(Table 3 and Fig. 2). These findings suggest that p53 is
not the sole regulator of VEGF. Different pathways
may exist for dissimilar tumor phenotypes. p53 and bcl-
2 may work together to regulate flk-1 expression and
tumor proliferation in colon hepatic metastasis. This
further supports the idea that VEGF may prevent
tumor cell apoptosis via the bcl-2 anti-apoptotic path-
way, and this event may be mediated through the flk-1
receptor.3 Bruns et al.3 demonstrated that tumor
apoptosis could not be prevented when flk-1 was inac-
tivated in a murine model.
In summary, hepatic metastases from colon cancer
were found to express VEGF and flk-1 that related to
tumor angiogenesis, proliferation, and apoptosis. High
levels of VEGF expression were associated with high
levels of flk-1 expression, consistent with the hypothesis
that tumor developopment may be stimulated by the
VEGF-flk-1 autocrine system. bcl-2 expression and the
coincidence of p53 and bcl-2 were associated with flk-1
expression. This suggests that p53 and bcl-2, especially
through the bcl-2 anti-apoptosis pathway, may mediate
tumor development via flk-1 to upregulate VEGF func-
tion. A large sampling study is warranted to clarify the
interaction of VEGF/flk-1 expression with bcl-2 and
p53, and its clinical significance, in colon cancer liver
metastases.
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